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Abstract
Ovarian transplantation is one of the key approaches to restoring fertility in women who became menopausal as a result of
cancer treatments. A major limitation of human ovarian transplants is massive follicular loss during revascularization. Here
we investigated whether sphingosine-1-phosphate or its receptor agonists could enhance neoangiogenesis and follicle
survival in ovarian transplants in a xenograft model. Human ovarian tissue xenografts in severe-combined-immunodeficient
mice were treated with sphingosine-1-phosphate, its analogs, or vehicle for 1–10 days. We found that sphingosine-1-
phosphate treatment increased vascular density in ovarian transplants significantly whereas FTY720 and SEW2871 had the
opposite effect. In addition, sphingosine-1-phosphate accelerated the angiogenic process compared to vehicle-treated
controls. Furthermore, sphingosine-1-phosphate treatment was associated with a significant proliferation of ovarian stromal
cell as well as reduced necrosis and tissue hypoxia compared to the vehicle-treated controls. This resulted in a significantly
lower percentage of apoptotic follicles in sphingosine-1-phosphate-treated transplants. We conclude that while
sphingosine-1-phosphate promotes neoangiogenesis in ovarian transplants and reduces ischemic reperfusion injury,
sphingosine-1-phosphate receptor agonists appear to functionally antagonize this process. Sphingosine-1-phosphate holds
great promise to clinically enhance the survival and longevity of human autologous ovarian transplants.
Citation: Soleimani R, Heytens E, Oktay K (2011) Enhancement of Neoangiogenesis and Follicle Survival by Sphingosine-1-Phosphate in Human Ovarian Tissue
Xenotransplants. PLoS ONE 6(4): e19475. doi:10.1371/journal.pone.0019475
Editor: Eric J. Bernhard, National Cancer Institute, United States of America
Received January 21, 2011; Accepted April 4, 2011; Published April 29, 2011
Copyright:  2011 Soleimani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National Institute of Health, HD053112 and R21HD061259 to Kutluk Oktay. The funder had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: koktay@fertilitypreservation.org
. These authors contributed equally to this work.
Introduction
Chemotherapy-induced infertility and ovarian failure are
significant quality of life issues in women. Ovarian cryopreserva-
tion prior to chemotherapy followed by auto-transplantation has
been performed to preserve and restore fertility in cancer survivors
[1–8]. Because ovarian grafts are transplanted against a vascular
bed on the pelvic sidewall [1], subcutaneously [2,3], or on the
remaining menopausal ovary [4,5] their survival is acutely
dependent on the neovascularization process, akin to skin grafting.
The initial ischemic phase, which occurs until the revasculariza-
tion process is completed is associated with massive primordial
follicle loss [9] and limits the longevity and success of ovarian
transplants (OT) [10,11]. Therefore, there is a great clinical need
to develop pharmacological strategies to enhance neoangiogenesis
after ovarian transplantation and to improve the clinical utility of
this procedure.
Sphingosine-1-phosphate (S1P) is a sphingolipid metabolite
which was originally shown to inhibit germ cell apoptosis induced
by radiation and chemotherapy in mice [12]. Recent work also
implicated S1P as a modulator of endothelial cell migration
[13,14], and angiogenesis in non-human non-reproductive tissues
[15]. It has been shown that S1P can provoke the formation of
cell-cell aggregates in differentiated endothelial cells [16] that act
as a predominant angiogenic stimulus by prompting vascular
endothelial cell growth, migration, and tube formation [17,18].
To date, five S1P receptors have been identified and cloned.
These S1P receptors are originally known as the endothelial
differentiation gene-1 (EDG-1) family of proteins [19] and include
S1P1 (EDG-1), S1P2 (EDG-5), S1P3 (EDG-3), S1P4 (EDG-6) and
S1P5 (EDG-8). The diverse effects of S1P are tissue specific which
is explained by some to be the result of variations in heterotrimeric
G proteins downstream of S1P receptors [20] or by its actions as
an intracellular messenger [21]. Previous studies indicated that the
angiogenic effect of S1P is mostly receptor driven but others
suggested an intracellular messenger mechanism [17,22,23].
Receptor mediated angiogenic effect of S1P is mainly through
S1P1 [16] and to some extent with S1P2-5 [24] receptors. Signal
cross-talk between S1P1 and angiogenesis related growth factor
receptors, such as the platelet-derived growth factor [25] and
VEGF [6] has also been demonstrated.
Recently, several synthetic S1P analogs have become commer-
cially available. One such agent is SEW2781, which is a selective
S1P1 receptor agonist. FTY720 is another S1P agonist which is
currently used in clinical trials as an immunosuppressant for renal
transplantation [26,27]. By virtue of its immunosuppressive effects,
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FTY720 has also been demonstrated to improve allograft survival
in various solid organ allo-transplant models such as liver [28] and
intestine [29]. FTY720 is phosphorylated in vivo by sphingosine
kinase and the phosphorylated form is a potent agonist of S1P1, 3,
4 and 5 receptors [30].
Given the recent evidence that S1P may play a positive role in
angiogenesis in non-reproductive cell lines and tissue
[13,15,23,31,32,33], we hypothesized that S1P and its agonists
could improve neoangiogenesis, and as a result, primordial follicle
survival during human ovarian cortical tissue transplantation. To
study the impact of S1P on OTs in vivo, we used a xenograft model
previously developed by us [34,35,36].
Results
Comparison of angiogenic effects of S1P, FTY720 and
SEW2871
To determine the effect of S1P and its analogs on neoangiogenesis
we used anti-CD31 (PECAM-1) antibody as a surface marker of new
blood vessels [37]. Angiogenesis was more prominent in S1P-treated
OTs in comparison with the vehicle-treated controls (23.767.2 vs.
13.962.1; p = 0.001) (Figures 1 and 2A–D). In contrast, FTY720 and
SEW2871 treatment was associated with reduced vascular density
compared to vehicle-treated controls (9.362.1 and 5.862.9
respectively, vs. 13.962.1; p,0.001) (Figures 1 and 2E,F).
S1P treatment also affected SC population. While there was a
significant decrease in SC density in vehicle-treated controls
compared to the baseline (200.9628.5 vs. 265.0661.5; p,0.001)
(Figure 1), S1P-treated grafts showed significantly higher SC
density compared to the baseline, the vehicle-treated control, and
any other experimental group (830.46115.1; p,0.001)
(Figure 2G–L). There was no difference between the vehicle-
treated control and the SEW2871-treated tissues in the SC density
(200.9628.5 vs. 226.3655.8; p.0.05). FTY720 treatment result-
ed in the lowest SC density of all experimental groups (142643;
p,0.001) (Figure 2K and Figure S1) while there was massive SC
proliferation in S1P-treated ovarian transplants as demonstrated
by PCNA staining. In contrast, a higher fraction of OTs contained
non-uniform acellular/hypocellular areas in the untransplanted
controls compared to S1P-treated OTs (16.7% vs. 0%, p = 0.007).
FTY720 and SEW2871 treatment was associated with a larger
fraction of grafts with.25% acellular areas (less than 30 cells/grid
area under high power field) compared to S1P (100% and 83.3%
vs. 0% respectively; p,0.05).
Because xenografted ovarian tissues are small and O2 diffusion
from peripheral tissues is conceivable, one can question whether
increased vascular density would actually improve tissue perfusion.
By HIF1alpha expression in the grafted tissues as an endogenous
hypoxia marker [38], S1P-treated OTs demonstrated significantly
reduced tissue hypoxia compared to vehicle-treated controls on
day 10 (6.966.6% vs. 2568.5% hypoxic area; p,0.05)
(Figure 2M–P) whereas FTY720 and SEW2871 treatment was
associated with massively increased tissue hypoxia compared to
vehicle-treated controls (75.769 and 57.2612 vs. 2568.5
respectively; p,0.05) (Figure 2Q,R). Overall, vascular density
and the percentage of hypoxic tissue area showed a strong negative
correlation (Spearman’s rank correlation coefficient: 20.764,
p,0.001) indicating that improved revascularization results in
the reduction of tissue hypoxia (Figure S2).
To demonstrate that S1P is enhancing neoangiogenesis by
inducing proliferation of the existing human blood vessels, we
studied alphaSMA expression. Anti-alphaSMA IHC demonstrated
a significantly lower density of mature blood vessels in S1P-
compared to vehicle-treated control, FTY720- and SEW2781-
treated OTs (2.061.2 vs. 5.160.8, 5.661.3 and 4.161.8
respectively; p,0.05) (Figure S2) indicating that S1P induced
proliferation and formation of new blood vessels as opposed to
enhancing the survival of pre-existing ones. However, adjacent
sections of CD31 positive vessels were also stained for alphaSMA
in most of the S1P-treated grafts, indicating that S1P can induce
neoangiogenesis from pre-existing mature vessels (Figure S2E,F).
Impact of S1P and its analogs on follicle survival
We then investigated whether enhanced neoangiogenesis
improved survival of primordial follicles (n of donors = 3; n of
grafts in each group S1P = 8, FTY720 or SEW2871 = 12). There
was a significant decrease in the percentage of apoptotic follicles in
S1P-treated xenografts compared to the vehicle-treated control-
and SEW2871- or FTY720-treated groups (6.8610.7 vs.
11.865.7, 15.964.2 and 17.964.0 respectively, p#0.001).
Compared to vehicle-treated controls, SEW2781 or FTY720 did
not have an impact on the percentage of apoptotic follicles in OTs,
Figure 1. The effect of S1P, SEW2871 and FTY720 on ovarian transplant revascularization and stromal cell population. S1P induces
ovarian angiogenesis (Left axis) and increases stromal cell population (Right axis) while its analogs, SEW2871 and FTY720 have the opposite effect,
10 days after grafting of ovarian transplantation. * Significantly different from control. # Significantly different from baseline ovarian tissue.
doi:10.1371/journal.pone.0019475.g001
S1P-Induced Human Ovarian Xenograft Survival
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indicating that S1P but not its analogs improves follicle survival.
Overall, vascular density and the percentage of apoptotic follicles
showed a negative correlation (Spearman’s rank correlation
coefficient: 20.257, p,0.01) in all groups confirming the
dependency of follicle survival on ovarian angiogenesis.
Does S1P accelerate neoangiogenesis?
Having shown that S1P but not its analogs improve ovarian
neoangiogenesis, we then investigated whether S1P treatment
accelerated this process (n of donors = 1; n of grafts in each group
= 12). While we did not find a significant difference in the density
of CD31-positive blood vessels between the vehicle-treated control
grafts and the baseline before day-3 after xenotransplantation, this
difference was detectable starting two days after xenotransplanta-
tion in the S1P-treated grafts (p = 0.001) (Figure 3). Even though
grafts in both S1P- and vehicle-treated control groups demon-
strated a significant rise in the density of CD31-positive blood
vessels by day-10 compared to baseline, the vascular density was
doubled in the S1P- compared to the vehicle-treated group
(32.265.2 vs. 16.561.1 respectively; p,0.001). The comparison
of follicle survival was not possible in this experiment due to the
low baseline follicle density.
By HIF1alpha staining, 100% of the surface area of OTs in
S1P- and vehicle-treated control groups demonstrated hypoxia
during the first four days after grafting but the intensity of staining
was lower in the S1P-treated OTs. The presence of hypoxia is
expected as these microvessels are known to become functional as
late as by day-4 [36,39,40]. However, hypoxia was reduced by
day-10 in the S1P-treated OTs compared to vehicle-treated
controls (5.666.3 vs. 20.866.8 respectively; p = 0.001).
Determining the contribution of the recipient site to
transplant revascularization using an acellularized
extracellular scaffold
Next, to determine whether S1P induces neoangiogenesis from
the recipient site, OT, or both, we substituted OTs with an
Figure 2. Impact of S1P and its analogues on neo-angiogenesis, stromal cell proliferation and tissue hypoxia. (A–F) Evaluation of
angogenic effect of S1P and its analogs in ovarian transplants by anti-CD31 IHC. S1P induces angiogenesis of ovarian transplants (D) while FTY720 (E)
or SEW2871 (F) treatment reduces it. Arrows show newly formed blood vessels positively stained for anti-CD31. (G–L) Evaluation of cell proliferation
by anti-PCNA expression. S1P induces (J) where as FTY720 (K) reduces stromal cell proliferation. SEW2871 (L) treatment does not affect stromal cell
proliferation compared to vehicle-treated control grafts. Arrows show proliferating stromal cell positively stained for PCNA. (M–R) Evaluation of
ovarian tissue hypoxia by HIF1a.While S1P (P) treatment reduces tissue hypoxia compared to vehicle-treatment. FTY720 (Q) and SEW2871
(R) treatment is associated with massive tissue hypoxia 10 days post-grafting. (Q) Arrow shows hypoxic ovarian follicles in a FTY720-treated graft.
(S) There is an inverse correlation between vascular density and hypoxic ovarian tissue surface area in the grafts, as determined by HIF1a staining.
This indicates that enhanced vascular density reduces hypoxia in ovarian transplants.
doi:10.1371/journal.pone.0019475.g002
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acellular human extracellular matrix scaffold (Alloderm). A
significantly higher density of murine blood vessels was detected
in S1P-treated versus vehicle-treated control alloderm grafts on
day-10 (6.460.5 vs. 4.260.7 respectively; p,0.005). There was
significant cell proliferation and migration into alloderm in both
vehicle-treated control and S1P-treated groups, but this was more
prominent in S1P-treated group (13967.4 vs. 62.363.8 respec-
tively; p,0.005) (Figure S3). These findings indicate that, S1P can
induce neoangiogenesis from the recipient tissue even in the
absence of ovarian grafts and S1P targets both the implantation
site and ovarian tissue to enhance graft survival.
Is S1P-induced neoangiogenesis and improved follicle
survival affected by ovarian tissue cryopreservation and
thawing process?
In the majority of fertility preservation cases, ovarian tissue is
cryopreserved before chemotherapy, and thawed later for
transplantation. Therefore, next we repeated the S1P- experiments
using frozen-thawed ovarian tissue to determine whether S1P had
the same beneficial effect on ovarian neoangiogenesis in frozen-
thawed tissue.
First, we did not find any difference in the density of CD31-
positive vessels between the fresh-fixed and cryopreserved-thawed
and fixed baseline ovarian tissues (5.560.6 vs. 5.760.6; p.0.05),
indicating that cryopreservation process itself did not morpholog-
ically affect pre-existing vascular structures. We then found that
S1P resulted in a significantly larger increase in vascular density
compared to vehicle-treated controls (28.563.7 vs. 12.360.8,
p = 0.001) after 10 days of xenografting when frozen thawed
ovarian tissue were used. This improvement was similar to that
seen with fresh ovarian transplants (Figure 1), hence proving that
S1P has the same pro-angiogenic effect both in fresh and frozen-
thawed grafts.
What is the impact of S1P on follicle survival in frozen-
thawed ovarian transplants?
To demonstrate the impact of S1P on follicle survival in an
experimental setting similar to clinical trials [1,3,11], ovarian tissue
from a two-year-old (n = 8 grafts in each group) was slow-frozen,
thawed and grafted as above described. AC3 IHC was used as a
marker of follicular apoptosis. The percentage of apoptotic follicles
was significantly higher in cryopreserved OTs compared to the
untransplanted tissue at baseline (14.663.4 vs. 3.360.6, p = 0.004),
indicating that cryopreservation process itself induces apoptotic follicle
death. S1P treatment significantly lowered the percentage of apoptotic
follicles with frozen-thawed OTs compared to xenografted vehicle-
treated controls (5.760.7 vs. 8.261.5; p = 0.006) (Figure 4A–D).
Does S1P improve follicle survival in OTs independent of
its antiapoptotic effects?
Previous studies have shown that S1P can rescue ovarian
primordial follicles from apoptotic death [12]. To verify that
improved neovascularization but not direct anti-apoptotic effects
of S1P resulted in reduced percentage of apoptotic follicles in OTs,
we correlated the vascular density with percentage of apoptotic
follicles. A significant inverse-correlation was observed between
the density of blood vessels and percentage of apoptotic follicles in
the xenografts (Spearman’s rank correlation coefficient:20.77;
p = 0.002) (Figure 4E), indicating that S1P-induced neoangiogen-
esis directly contributed to post-ovarian transplant follicle survival.
Further, because tissue hypoxia showed a strong negative
correlation with vascular density (Figure S2), we concluded that
S1P treatment enhances follicle survival in OTs by reducing tissue
hypoxia by way of increased vascular density.
Discussion
Despite recent success in the development of ovarian tissue
cryopreservation and transplantation techniques, massive loss of
primordial follicles during the initial days after the ovarian
transplantation limits the success of the procedure. Ischemic
reperfusion injury induced by oxygen-derived free radicals and
lipid peroxidation leading to primordial follicle loss have been
cited as the most significant drawback of human ovarian tissue
transplantation [41]. Others have suggested that prevention of
oxidative stress during transplantation will lead to prevention of
ischemic reperfusion injury and increase ovarian follicle survival
consequently [10].
Given the recent preliminary evidence that S1P may enhance
neoangiogenesis, we studied the effect of S1P on early angiogenesis
after human ovarian transplantation that is crucial for the graft
survival. Our data showed that S1P not only enhanced the mean
density of newly formed blood vessels in OTs, but it also
accelerated neoangiogenesis compared to vehicle-treated controls.
Figure 3. Impact of S1P on early angiogenesis after ovarian transplantation. S1P-treated ovarian transplants show significantly higher
density of microvasculature by as early as two days after transplantation. * Significantly different from matching vehicle-treated control.
# Significantly different from baseline.
doi:10.1371/journal.pone.0019475.g003
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This acceleration of neoangiogenesis by S1P is expected to be of
high clinical significance because the longer the initial ischemia the
higher will be the follicle losses from OTs. Consistent with our
hypothesis, we found that the enhancement of ovarian angiogen-
esis was associated with reduced tissue hypoxia and a lower
percentage of apoptotic follicles.
After 10 days of xenografting, the higher density of CD31-
positive blood vessels and the reduced number of mature blood
vessels stained by alphaSMA in S1P-treated grafts indicated
enhanced proliferation of new blood vessels. There was a smaller
but significant increase in vascular density in untreated xenografts
compared to baseline on day-10, which can be explained by the
wound healing process in the grafts. Similar results were obtained
after OT with cryopreserved human tissue, indicating that our
cryopreservation protocol did not affect the neoangiogenesis in
OTs.
Because S1P has a well-known direct anti-apoptotic effect on
oocytes [12], one could question whether the benefit of S1P is via
enhanced angiogenesis, improved oocyte survival, or both. First,
we showed in earlier studies that ovarian follicle growth in human
ovarian xenografts correlates with vascular density [36]. Second,
in the current work, we analyzed the correlation between vascular
density, apoptotic follicle death, and tissue hypoxia. We found that
the vascular density was inversely correlated with the percentage
of hypoxic tissue and apoptotic follicles in OTs. Therefore, while a
contributory direct anti-apoptotic effect on follicles cannot be
ruled out, our data indicates that S1P protects follicles in OTs by
enhancing the revascularization process.
To study the impact of S1P on regeneration of vascular
structures from the recipient site in isolation, we substituted
ovarian transplants with alloderm, an acellular extracellular
scaffold. Because alloderm is immunologically inert and contains
no cellular or vascular structures [42], any cells or blood vessels
which were detected after grafting would have to originate from
the recipient. We found that S1P significantly stimulated
neoangiogenesis and SC proliferation from the murine dorsal
muscles even in the absence of ovarian tissue. The latter effect may
indicate that S1P’s action is both on the recipient site and the
ovarian graft and thus S1P may also be beneficial in improving
ovarian transplantation to heterotopic locations such as subcuta-
neous [3]. This finding also indicates that S1P treatment may also
be useful in improving neoangiogenesis in other non-reproductive
tissue grafting and organ transplant settings.
Surprisingly, and in contrast to S1P, S1P receptor agonists
impeded neovascularization and induced tissue hypoxia. Reduc-
tion of angiogenesis by SEW2871, a specific agonist of S1P1,
suggests that the pro-angiogenic effect of S1P1 in human ovarian
tissue maybe via a non-receptor mechanism. It is possible that
similar to its action in bovine aortic endothelial [17] and muscular
smooth muscle cells [22,23], S1P1 acts primarily as an
intracellular messenger to promote neoangiogenesis in OTs.
Consistent with the previous data showing that FTY720 has
anti-angiogenetic effects in a mouse melanoma model [43] we also
found that FTY720 inhibited angiogenesis and induced hypoxia in
OTs. Currently, ovarian transplantation is performed with
autologous or genetically identical tissue but it has been
hypothesized that this procedure can be performed among
genetically non-identical individuals when safer immune-suppres-
sion agents such as FTY20 have become available. Even though
FTY720 is proven to be effective in preventing organ rejection
after liver [28] and kidney transplantation [44,45,46], it may not
be suitable in OT transplantation due to its antiangiogenic effect.
Figure 4. Impact of S1P on follicle survival in frozen-thawed ovarian transplants. Frozen-thawed ovarian tissue was transplanted to SCID
mice and percentage of apoptotic follicles were compared between S1P-treated and vehicle-treated control grafts. (A–D) Histomorphological
evaluation of apoptosis induced by cryopreservation and/or transplantation. The percentage of apoptotic follicles was significantly lower in fresh
baseline ovarian tissue (A) compared to cryopreserved-untransplanted ovarian tissue (B) indicating that cryopreservation process itself induces
apoptotic ovarian follicle death. S1P treatment results in significantly decrease in the density of apoptotic follicles (D) compared to the vehicle-
treated group (C). Arrows indicate apoptotic ovarian follicles. (E) Inverse correlation of apoptotic follicle death with vascular density indicating that
improved vascularization by S1P enhances follicle survival.
doi:10.1371/journal.pone.0019475.g004
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Interestingly, FTY720’s immunosuppressive effect, which is due to
its inhibition of T-lymphocyte infiltration, also appears to be
receptor-independent [47–50].
Ovarian SC [51] and ovarian extracellular matrix have been
reported to have an important role in normal ovarian function,
follicle growth, and survival [52,53]. We observed a significant
reduction of the SC population in grafted OTs compared to the
baseline. S1P treatment enhanced SC survival and proliferation,
whereas FTY720 had the opposite effect. This indicates that in
addition to enhancing angiogenesis, S1P treatment may offer a
supplementary mechanism of support for OT survival.
It can be questioned whether different dosing of S1P agonists
could have changed the outcome. We are doubtful that the dose
we used was ineffective as both agonists reduced the vascular
density compared to vehicle controls confirming a real biological
effect. If the local concentration were ineffective, we would have
seen no biological effect by the agonists. Further pointing towards
the specificity and the existence of the action by the agonists,
FTY720 and SEW2871 had differential effects on certain markers
such as the stromal cell density; while the former significantly
reduced it the latter did not have an effect (Table S1).
To our knowledge, this study is not only the first study to
investigate the effect of S1P and its analogs to improve the survival
of human OTs, but it is also novel in showing the role of S1P in
human transplant angiogenesis in general. As such, while our
findings indicate that S1P may improve the success of human OTs
by enhancing and accelerating angiogenesis and SC proliferation,
they may also lead to further examination of the role of S1P in
angiogenesis in other tissues. While our findings justify a clinical
trial to prove the clinical benefit of S1P in ovarian transplantation,
we need to develop longer acting S1P derivatives or targeted
delivery systems to be able to practically administer this agent to
patients.
Materials and Methods
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
study protocol was approved by the institutional review board of
New York Medical College (IRB No. L-9178) and written
informed consent was obtained from all participants involved in
the study and in case of children, the consent was signed by
parents. All surgery was performed under anesthesia, and all
efforts were made to minimize suffering. Ovarian tissue fragments
were obtained from consenting females patients (n = 5, age range
2–37) undergoing ovarian tissue freezing before chemotherapy.
Most of the experiments were performed with fresh tissue to
eliminate the possible effect of cryopreservation. Frozen ovarian
tissue was only used to study the impact of S1P on follicle survival
in frozen-thawed ovarian transplants.
Human ovarian tissue preparation and transplantation
Human ovarian cortical pieces were prepared as one-mm3
pieces and were transplanted into the dorsal muscles of severe-
combined-immunodeficient (SCID) mice as previously described
[36]. Briefly, ovarian tissue fragments were collected in a modified
M199 medium (Gibco, Invitrogen, Carlsbad, USA) while the
recipient animals were being anesthetized by Ketamine 75 mg/kg,
intraperitoneal (i.p.) (Ketathesia, Dublin, OH, USA) and Xylazine
1 mg/kg i.p. (AnaSed, Shanandoah, Iowa, USA). Analgesia was
provided by i.p. injection of buprenorphine 0.1 mg/kg (Buprenex,
Reckitt & Colman, Hull, UK) before surgery. A small incision was
made in the skin on the dorsal midline of the recipient animal.
Using fine watchmakers’ forceps, ovarian tissue fragments were
randomly picked and xenotransplanted into the dorsal muscles
and skin incisions were closed under aseptic conditions.
Comparison of angiogenic effects of S1P, FTY720 and
SEW2871
To compare the angiogenic effects of S1P, SCID mice (n = 8 in
each group) xenotransplanted with human ovarian tissue (No. of
patients = 3) received either S1P (200 mM)(n = 8 grafts) using Alzet
mini-osmotic pumps (Durect, Cupertino, Ca, USA) or FTY720
(2 mg/kg)(n = 12 grafts) (Cayman chemical, MI,USA) or
SEW2871 (5 mg/kg)(n = 12) intravenous. Previous work has
shown that revascularization of human ovarian xenografts into
murine occurs within 3 to 4 days of the transplantation [36].
Therefore, to determine the angiogenic effect of S1P, FTY720 or
SEW2871, mice received the drugs for the first 4 days after
xenografting. Because S1P has a very short plasma half-life, single
dose administration would not be effective. Therefore, a
subcutaneous mini-osmotic pump with a flow rate of 8 ml/hour
was used to administer S1P (200 mM) continuously for four days
via a fine polyethylene catheter tubing (Durect, Cuperino, Ca,
USA) directly to the grafts. Mini-osmotic pumps generally need
two hours before fully functioning in vivo. To provide adequate
local concentration of S1P immediately after xenografting, ovarian
tissues were placed in the handling medium containing S1P.
Immediately before transplantation 200 mM of S1P was injected
into the muscular pocket where the xenograft was placed, before
closing the skin. Control animals received normal saline via
identical osmotic pumps. In the initial experiments we used fresh
ovarian tissue, to control for possible effect of cryopreservation on
angiogenesis and follicle apoptosis. Grafts were recovered 10 days
after xenografting and processed for quantification of angiogenesis,
assessment of follicular apoptosis and hypoxia in OTs.
The impact of S1P on early angiogenesis after
xenografting
This experiment was designed based on the data obtained from
previous experiment, to characterize the early events occurring
during the first days after grafting and administration of S1P.
Ovarian tissues were obtained from a 37 year-old consenting
female and 12 ovarian tissue pieces were xenotransplanted into the
dorsal muscle of SCID mice in each group. Mice received S1P
(200 mM) using Alzet mini-osmotic pumps for the first 4 days
following xenografting. Control group received normal saline via
identical osmotic pumps. Animals were sacrificed daily from days
1–4 and on day 10, and the grafts were recovered. After tissue
embedding, tissues were sectioned at 4 mm and were stained for
CD31 to determine the vascular density as described later.
Determining the contribution of recipient site to
transplant revascularization using an acellularized
extracellular scaffold
We used a human acellularized extracellular matrix scaffold
(Alloderm, LifeCell, NJ, USA) to determine whether S1P is
enhancing angiogenesis from the murine recipient into human
OTs. Alloderm is currently used in practice for the repair of tissue
defects, reconstruction, and bridging neovascularization from
adjacent tissue edges [54]. 12 pieces of alloderm were xenografted
similar to ovarian tissue as described above and S1P was
administered for 4 days with osmotic mini-pumps, identical to
previous experiments. Alloderm grafts were recovered at day-10.
Control animals with similar alloderm xenografts received only
normal saline (vehicle). Recovered alloderm grafts were evaluated
S1P-Induced Human Ovarian Xenograft Survival
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for quantification of angiogenesis by anti-mouse CD-31 immuno-
histochemical (IHC) staining (Abcam, MA, USA) and assessment
of cellular proliferation by proliferating cell nuclear antigen
(PCNA)(Abcam, MA, USA) expression [36,55].
Histology, stromal and vascular density assessment, and
immunohistochemistry
Histomorphological examination of paraffin-embedded OT
grafts was performed after serially sectioning the entire graft at
4 mm. One out of every ten sections was selected for each kind of
staining. H&E staining was used to study the tissue architecture,
necrosis, and to visualize ovarian stromal cell (SC) for quantifi-
cation. SC were counted at high-power filed (6400) in a grid area
of 0.15 mm2 at five randomly selected positions in 25 different
sections [36,56]. IHC staining against PCNA was performed to
confirm cell proliferation in the grafted tissues in various
experimental groups.
To study neoangiogenesis, epithelial cells of new blood vessels
were stained using anti-human CD31 IHC (Ventana, Lille,
France). Mature blood vessels were evaluated by means of anti-
alpha smooth muscle actin IHC staining (AlphaSMA) (Ventana,
Lille, France). To calculate vascular density, CD31 or AlphaSMA
staining vessels were counted at high-power filed (6400) in a grid
area of 0.15 mm2 at five randomly selected positions in 25
different sections [36,56]. The mean value was used as the final
vascular density for each graft.
Apoptotic death was evaluated by anti-active caspase-3 staining
(AC3)(R&D systems Minneapolis, USA). Reddish-brown coloring
of the cytoplasm/nucleus of the follicles was specified as positive
staining. The ratio of apoptotic follicles to total follicular numbers
was calculated and compared. Data were compared to baseline
ovarian tissue and transplanted vehicle-treated OTs as control.
The level of hypoxia in the grafted tissues were evaluated by the
expression of hypoxia inducible factor 1 alpha (HIF1alpha) IHC
(Bethyl Laboratories, TX, USA). The ratio of hypoxic area to total
surface area of ovarian tissue was compared among different
experimental groups.
For negative control, the primary antibody was omitted in each
different IHC staining.
Statistical Analysis
Statistical analysis was performed with the SPSS 17 for
Windows package (SPSS Inc., Chicago, IL). Levene’s test of
homogeneity of variances (p,0.01) and Kolmogorov-Smirnov test
of normality (p,0.01) were performed to choose the appropriate
statistical test. Continuous data (presented as mean6SD) were
analyzed by one-way analysis of variance followed by the LSD
post hoc test. The non-parametric data were analyzed with
Kruskal Wallis test followed by multiple pair-wise comparisons
using Mann-Whitney U-test (a value was adjusted). Fisher’s exact
test was performed to analyze the relation between two categorical
variables. Non-parametric correlation between the percentage of
apoptotic follicles and the number of blood vessels was analyzed
with the Spearman’s test. When the P value was ,0.05, the
difference was considered statistically significant.
Supporting Information
Figure S1 Evaluation of the stromal cell density in
ovarian transplants treated with S1P, FTY720, or
SEW2871. Cell counts after H&E staining of ovarian grafts show
that S1P results in higher stromal cells density compared to
baseline. FTY720 treatment reduces stromal cell density com-
pared to all experimental groups. SEW2871 treatment does not
improve stromal cell density and is comparable to grafted vehicle-
treated control.
(TIF)
Figure S2 Evaluation of the impact of S1P on mature
blood vessels in ovarian grafts. (A-F) Anti-human aSMA
IHC. S1P-treated human ovarian grafts (D and E) demonstrated
lower density of mature blood vessels compared to baseline (A) and
vehicle-treated controls (B). (F) CD31 staining of the same vessel as
panel E (adjacent section) indicates that that S1P can induce
neoangiogenesis from pre-existing mature blood vessel. (G) Two
functioning blood vessels in S1P-treated graft containing red blood
cells 10 days post grafting.
(TIF)
Figure S3 Cell proliferation and migration into allo-
derm grafts in animals treated with S1P or its analogs.
(A–F) PCNA staining shows significantly higher proliferation of
ovarian stromal cells into alloderm in S1P-treated animals (D)
compared to vehicle-treated controls (C). FTY720 (E) and
SEW2871 (F) do not have an affect compared to vehicle-treated
control.
(TIF)
Table S1 Differential impact of S1P and its analogues on
ovarian xenografts. q: Significantly increased, Q: Significantly
decreased, 2: No significant effect.
(DOC)
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